Disease · MONDO_0016748

hemangioblastoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hemangioblastoma. Diseases, record MONDO_0016748. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016748

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hemangioblastoma; Open Targets
Open Targets ID: MONDO_0016748; Open Targets
Other names: angioblastoma, capillary hemangioblastoma; Open Targets
Disease Ontology: DOID:5241; Disease Ontology
MeSH: D018325; MeSH
NCI Thesaurus: C3801; NCI Thesaurus
Orphanet: ORPHA:252054; Orphanet
Highest stage of its drugs: Approval, for 1 of its 5 drugs, from FDA; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BELZUTIFAN	CHEMBL4585668	Small molecule	Approval	FDA	1	0	0	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VATALANIB	CHEMBL101253	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
EPAS1	Endothelial PAS domain-containing protein 1	1	Endothelial PAS domain-containing protein 1 inhibitor	Approval	https://conductscience.org/library/genes/2034	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00589784	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase 2	50	2016-01-25	CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT05424016	Propranolol and Von Hippel-Lindau Disease	Not applicable	85		Hemangioblastoma of CNS, Von Hippel-Lindau Disease	PROPRANOLOL	Its record names the disease	ClinicalTrials.gov
NCT00052013	Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584	Phase 2	11		Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma	VATALANIB	Its record names the disease	ClinicalTrials.gov
NCT01015300	Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease	Early phase 1	1		Hemangioblastomas, Von Hippel Lindau Disease	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016748

GET https://conductscience.org/api/diseases/v1/MONDO_0016748/drugs

API reference For AI assistants